Neoadjuvant Sintilimab and Chemotherapy in Patients with Potentially Resectable Esophageal Squamous Cell Carcinoma (KEEP-G 03): an Open-Label, Single-Arm, Phase 2 Trial.
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2023）
Key words
biomarkers,tumor,clinical trials,phase II as topic,gastrointestinal neoplasms,immunotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined